These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30666285)

  • 21. Restriction of Pharmacoepidemiologic Cohorts to Initiators of Medications in Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults.
    Zhang HT; McGrath LJ; Ellis AR; Wyss R; Lund JL; Stürmer T
    Am J Epidemiol; 2019 Jul; 188(7):1371-1382. PubMed ID: 30927359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research.
    Schneeweiss S; Stürmer T; Maclure M
    Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S51-9. PubMed ID: 15073755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias.
    Sun JW; Wang R; Li D; Toh S
    Am J Epidemiol; 2022 Mar; 191(4):711-723. PubMed ID: 35015823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study.
    Webster-Clark M; Ross RK; Lund JL
    Am J Epidemiol; 2021 Jul; 190(7):1341-1348. PubMed ID: 33350433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impacts of agroforestry interventions on agricultural productivity, ecosystem services, and human well-being in low- and middle-income countries: A systematic review.
    Castle SE; Miller DC; Ordonez PJ; Baylis K; Hughes K
    Campbell Syst Rev; 2021 Jun; 17(2):e1167. PubMed ID: 37131923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoepidemiology: An Overview.
    Sabaté M; Montané E
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observational studies of treatment effectiveness: worthwhile or worthless?
    Sharma M; Nazareth I; Petersen I
    Clin Epidemiol; 2019; 11():35-42. PubMed ID: 30588122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them.
    Fu EL; van Diepen M; Xu Y; Trevisan M; Dekker FW; Zoccali C; Jager K; Carrero JJ
    Clin Kidney J; 2021 May; 14(5):1317-1326. PubMed ID: 33959262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bias and confounding: pharmacoepidemiological study using administrative database].
    Nojiri S
    Yakugaku Zasshi; 2015; 135(6):793-808. PubMed ID: 26028416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
    Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
    Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study.
    Dong YH; Alcusky M; Maio V; Liu J; Liu M; Wu LC; Chang CH; Lai MS; Gagne JJ
    BMJ Open; 2017 Mar; 7(3):e012997. PubMed ID: 28363921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Confounding by indication in epidemiologic studies of commonly used analgesics.
    Signorello LB; McLaughlin JK; Lipworth L; Friis S; Sørensen HT; Blot WJ
    Am J Ther; 2002; 9(3):199-205. PubMed ID: 11941379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Observational designs in clinical multiple sclerosis research: Particulars, practices and potentialities.
    Jongen PJ
    Mult Scler Relat Disord; 2019 Oct; 35():142-149. PubMed ID: 31394404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review.
    Levintow SN; Nielson CM; Hernandez RK; Breskin A; Pritchard D; Lash TL; Rothman KJ; Gilbertson D; Muntner P; Critchlow C; Brookhart MA; Bradbury BD
    Pharmacoepidemiol Drug Saf; 2023 Jun; 32(6):599-606. PubMed ID: 36965103
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.